ADAlexey V. Danilov

Alexey V. Danilov

*This is an algorithmically generated author record based on publicly available information.

Alexey V. Danilov has a total of 9 co-authors. Here are the top co-authors by number of shared publications:

  • J. Claire Godbersen

    Authors' Affiliations: Departments of Medicine and Pathology, Dartmouth-Hitchcock Medical Center, Lebanon; Department of Pharmacology and Toxicology, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire; and Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts

    2 shared publications
  • Olga V. Danilova

    Authors' Affiliations: 1Departments of Medicine and 2Pathology, Dartmouth-Hitchcock Medical Center, Lebanon; 3Department of Pharmacology and Toxicology, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire; and 4Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts

    2 shared publications
  • Alan Eastman

    Authors' Affiliations: 1Departments of Medicine and 2Pathology, Dartmouth-Hitchcock Medical Center, Lebanon; 3Department of Pharmacology and Toxicology, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire; and 4Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts

    1 shared publication
  • Brock C. Christensen

    Pharmacology and Toxicology Geisel School of Medicine at Dartmouth Lebanon NH USA

    1 shared publication
  • Jennifer R. Brown

    Authors' Affiliations: 1Departments of Medicine and 2Pathology, Dartmouth-Hitchcock Medical Center, Lebanon; 3Department of Pharmacology and Toxicology, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire; and 4Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts

    1 shared publication
  • Leigh A. Humphries

    Medicine Dartmouth‐Hitchcock Medical Center Lebanon NH USA

    1 shared publication

Latest Publications

  • The Nedd8-Activating Enzyme Inhibitor MLN4924 Thwarts Microenvironment-Driven NF-κB Activation and Induces Apoptosis in Chronic Lymphocytic Leukemia B Cells

    by J. Claire Godbersen, Leigh Ann Humphries, Olga V. Danilova, Peter E. Kebbekus, Jennifer R. Brown, Alan Eastman, Alexey V. Danilov

    Background: Stromal-mediated signaling enhances NF-κB pathway activity in chronic lymphocytic leukemia (CLL) B cells, leading to cell survival and chemoresistance. Ubiquitination of IκBα may partially account for constitutive activation of NF-κB. MLN4924 is an investigational agent that inhibits the Nedd8-activating enzyme, thereby neutralizing Cullin-RING ubiquitin ligases and preventing degradation of their substrates. Experimental Design: We conducted a preclinical assessment of MLN4924 in CLL. Primary CLL cells were cocultured in vitro with CD40L-expressing stroma to mimic the prosurvival conditions present in lymphoid tissue. The effect of MLN4924 on CLL cell apoptosis, NF-κB pathway activity, Bcl-2 family members, and cell cycle was assessed by flow cytometry, Western blotting, PCR, and immunocytochemistry. Results: CD40L-expressing stroma protected CLL cells from spontaneous apoptosis and induced resistance to multiple drugs, accompanied by NF-κB activation and Bim repression. Treatment with MLN4924 induced CLL cell apoptosis and circumvented stroma-mediated resistance. This was accompanied by accumulation of phospho-IκBα, decreased nuclear translocation of p65 and p52 leading to inhibition of both the canonical and noncanonical NF-κB pathways, and reduced transcription of their target genes, notably chemokines. MLN4924 promoted induction of Bim and Noxa in the CLL cells leading to rebalancing of Bcl-2 family members toward the proapoptotic BH3-only proteins. siRNA-mediated knockdown of Bim or Noxa decreased sensitivity to MLN4924. MLN4924 enhanced the antitumor activity of the inhibitors of B-cell receptor (BCR)–associated kinases. Conclusions: MLN4924 disrupts NF-κB activation and induces Bim expression in CLL cells, thereby preventing stroma-mediated resistance. Our data provide rationale for further evaluation of MLN4924 in CLL. Clin Cancer Res; 20(6); 1576–89. ©2014 AACR.


  • Pro‐apoptotic TP53 homolog TAp63 is repressed via epigenetic silencing and B‐cell receptor signalling in chronic lymphocytic leukaemia

    by Leigh A. Humphries, J. Claire Godbersen, Olga V. Danilova, Prabhjot Kaur, Brock C. Christensen, Alexey V. Danilov

    Summary: Chronic lymphocytic leukaemia (CLL) is an accumulative disorder marked by deficient apoptosis. The TP53 homolog TAp63 promotes apoptosis and chemosensitivity in solid tumours and its deregulation may contribute to CLL cell survival. We found that TAp63α was the most prevalent TP63 isoform in CLL. Compared to healthy B cells, TAp63 mRNA was repressed in 55·7% of CLL samples. TP63 promoter methylation was high in CLL and inversely correlated with TP63 protein expression in B‐cell lymphoma cell lines. siRNA‐mediated knockdown of TP63 resulted in partial protection from spontaneous apoptosis accompanied by reductions in PMAIP1 (NOXA), BBC3 (PUMA), and BAX mRNA in CLL cells and increased proliferation of Raji lymphoma cells. TAp63 mRNA levels were higher in CLL with unmutated IGHV. B‐cell receptor (BCR) engagement led to repression of TP63 mRNA expression in malignant B cells, while pharmacological inhibition of BCR signalling prevented TP63 downregulation. MIR21, known to target TAp63, correlated inversely with TAp63 expression in CLL, and BCR‐mediated downregulation of TP63 was accompanied by MIR21 upregulation in most CLL samples. Our data illustrate the pro‐apoptotic function of TP63, provide insights into the mechanisms of BCR‐targeting agents, and establish a rationale for designing novel approaches to induce TP63 in CLL and B‐cell lymphoma.